{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:44:34Z","timestamp":1794361474208,"version":"4.9.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,11,5]],"date-time":"2015-11-05T00:00:00Z","timestamp":1446681600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novartis Pharma AG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1007\/s11102-015-0692-z","type":"journal-article","created":{"date-parts":[[2015,11,5]],"date-time":"2015-11-05T10:23:14Z","timestamp":1446718994000},"page":"138-148","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":148,"title":["Osilodrostat, a potent oral 11\u03b2-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing\u2019s disease"],"prefix":"10.1007","volume":"19","author":[{"given":"Maria","family":"Fleseriu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosario","family":"Pivonello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Young","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir H.","family":"Hamrahian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark E.","family":"Molitch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chikara","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoaki","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Shimatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Hilliard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Sauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beverly MK","family":"Biller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Bertagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,5]]},"reference":[{"issue":"9996","key":"692_CR1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/S0140-6736(14)61375-1","volume":"386","author":"A Lacroix","year":"2015","unstructured":"Lacroix A, Feelders RA, Stratakis CA, Nieman LK (2015) Cushing\u2019s syndrome. Lancet 386(9996):913\u2013927","journal-title":"Lancet"},{"issue":"7","key":"692_CR2","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1210\/jc.2007-2734","volume":"93","author":"BMK Biller","year":"2008","unstructured":"Biller BMK, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, Buchfelder M, Colao A, Hermus AR, Hofland LJ, Klibanski A, Lacroix A, Lindsay JR, Newell-Price J, Nieman LK, Petersenn S, Sonino N, Stalla GK, Swearingen B, Vance ML, Wass JA, Boscaro M (2008) Treatment of adrenocorticotropin-dependent Cushing\u2019s syndrome: a consensus statement. J Clin Endocrinol Metab 93(7):2454\u20132462","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"692_CR3","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1210\/er.2013-1048","volume":"36","author":"R Pivonello","year":"2015","unstructured":"Pivonello R, De Leo M, Cozzolino A, Colao A (2015) The treatment of Cushing\u2019s disease. Endocr Rev 36(4):385\u2013486","journal-title":"Endocr Rev"},{"issue":"1","key":"692_CR4","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ecl.2007.10.010","volume":"37","author":"R Pivonello","year":"2008","unstructured":"Pivonello R, De Martino MC, De Leo M, Lombardi G, Colao A (2008) Cushing\u2019s syndrome. Endocrinol Metab Clin N Am 37(1):135\u2013149","journal-title":"Endocrinol Metab Clin N Am"},{"issue":"5","key":"692_CR5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/nrendo.2011.12","volume":"7","author":"NA Tritos","year":"2011","unstructured":"Tritos NA, Biller BM, Swearingen B (2011) Management of Cushing disease. Nat Rev Endocrinol 7(5):279\u2013289","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"692_CR6","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1530\/EJE-13-0634","volume":"170","author":"C Dimopoulou","year":"2013","unstructured":"Dimopoulou C, Schopohl J, Rachinger W, Buchfelder M, Honegger J, Reincke M, Stalla GK (2013) Long-term remission and recurrence rates after first and second transsphenoidal surgery for Cushing\u2019s disease: care reality in the Munich Metropolitan Region. Eur J Endocrinol 170(2):283\u2013292","journal-title":"Eur J Endocrinol"},{"key":"692_CR7","unstructured":"Novartis Pharma AG (2013) Signifor summary of product characteristics. http:\/\/www.signifor.com\/european-product-characteristics.jsp"},{"key":"692_CR8","unstructured":"Novartis Pharmaceuticals Corporation (2012) Signifor prescribing information. http:\/\/www.pharma.us.novartis.com\/product\/pi\/pdf\/signifor.pdf"},{"key":"692_CR9","unstructured":"Corcept Therapeutics (2012) Mifepristone (Korlym) prescribing information. http:\/\/www.corcept.com\/prescribinginfo.pdf"},{"issue":"6","key":"692_CR10","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1210\/jc.2011-3350","volume":"97","author":"M Fleseriu","year":"2012","unstructured":"Fleseriu M, Biller BM, Findling JW, Molitch ME, Schteingart DE, Gross C (2012) Mifepristone, a glucocorticoid receptor antagonist, produces clinical and metabolic benefits in patients with Cushing\u2019s syndrome. J Clin Endocrinol Metab 97(6):2039\u20132049","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"692_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cen.12345","volume":"80","author":"MR Gadelha","year":"2014","unstructured":"Gadelha MR, Vieira NL (2014) Efficacy of medical treatment in Cushing\u2019s disease: a systematic review. Clin Endocrinol (Oxf) 80(1):1\u201312","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"692_CR12","doi-asserted-by":"crossref","first-page":"R19","DOI":"10.1530\/JOE-14-0300","volume":"223","author":"D Cuevas-Ramos","year":"2014","unstructured":"Cuevas-Ramos D, Fleseriu M (2014) Treatment of Cushing\u2019s disease: a mechanistic update. J Endocrinol 223(2):R19\u2013R39","journal-title":"J Endocrinol"},{"issue":"3","key":"692_CR13","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1007\/s11102-012-0397-5","volume":"15","author":"M Fleseriu","year":"2012","unstructured":"Fleseriu M, Petersenn S (2012) Medical management of Cushing\u2019s disease: what is the future? Pituitary 15(3):330\u2013341","journal-title":"Pituitary"},{"issue":"2","key":"692_CR14","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s12020-013-0098-5","volume":"46","author":"D Ferone","year":"2014","unstructured":"Ferone D, Pivonello C, Vitale G, Zatelli MC, Colao A, Pivonello R (2014) Molecular basis of pharmacological therapy in Cushing\u2019s disease. Endocrine 46(2):181\u2013198","journal-title":"Endocrine"},{"issue":"4","key":"692_CR15","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1210\/jc.2012-3200","volume":"98","author":"X Bertagna","year":"2013","unstructured":"Bertagna X, Guignat L (2013) Approach to the Cushing\u2019s disease patient with persistent\/recurrent hypercortisolism after pituitary surgery. J Clin Endocrinol Metab 98(4):1307\u20131318","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"692_CR16","doi-asserted-by":"crossref","first-page":"746","DOI":"10.4158\/EP14147.RA","volume":"20","author":"AH Hamrahian","year":"2014","unstructured":"Hamrahian AH, Yuen KC, Hoffman AR, the AACE Neuroendocrine and Pituitary Scientific Committee (2014) AACE\/ACE disease state clinical review: medical management of Cushing disease. Endocr Pract 20(7):746\u2013757","journal-title":"Endocr Pract"},{"issue":"5","key":"692_CR17","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1210\/jc.2013-3628","volume":"99","author":"F Castinetti","year":"2014","unstructured":"Castinetti F, Guignat L, Giraud P, Muller M, Kamenicky P, Drui D, Caron P, Luca F, Donadille B, Vantyghem MC, Bihan H, Delemer B, Raverot G, Motte E, Philippon M, Morange I, Conte-Devolx B, Quinquis L, Martinie M, Vezzosi D, Le Bras M, Baudry C, Christin-Maitre S, Goichot B, Chanson P, Young J, Chabre O, Tabarin A, Bertherat J, Brue T (2014) Ketoconazole in Cushing\u2019s disease: is it worth a try? J Clin Endocrinol Metab 99(5):1623\u20131630","journal-title":"J Clin Endocrinol Metab"},{"issue":"OC6","key":"692_CR18","first-page":"5","volume":"34","author":"E Daniel","year":"2014","unstructured":"Daniel E, Aylwin S, Mustafa O, Ball S, Munir A, Boelaert K, Chortis D, Cuthbertson DJ, Daousi C, Rajeev S, Davis J, Cheer K, Drake W, Gunganah K, Grossman A, Gurnell M, Powlson A, Karavitaki N, Huquet I, Kearney T, Mohit K, Meeran K, Hill N, Rees A, Trainer PJ, Lansdown AJ, Minder A-EH, Newell-Price J (2014) Effectiveness of metyrapone in 195 patients with Cushing\u2019s syndrome. Endocr Abstr 34:OC6.5","journal-title":"Endocr Abstr"},{"issue":"4","key":"692_CR19","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1210\/jc.2013-2117","volume":"99","author":"X Bertagna","year":"2014","unstructured":"Bertagna X, Pivonello R, Fleseriu M, Zhang Y, Robinson P, Taylor A, Watson CE, Maldonado M, Hamrahian AH, Boscaro M, Biller BM (2014) LCI699, a potent 11\u03b2-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing\u2019s disease: results from a multicenter, proof-of-concept study. J Clin Endocrinol Metab 99(4):1375\u20131383","journal-title":"J Clin Endocrinol Metab"},{"key":"692_CR20","unstructured":"American Heart Association (2014) Understanding blood pressure readings. http:\/\/www.heart.org\/HEARTORG\/Conditions\/HighBloodPressure\/AboutHighBloodPressure\/Understanding-Blood-Pressure-Readings_UCM_301764_Article.jsp"},{"issue":"1","key":"692_CR21","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1210\/jc.2006-1328","volume":"92","author":"G Assi\u00e9","year":"2007","unstructured":"Assi\u00e9 G, Bahurel H, Coste J, Silvera S, Kujas M, Dugu\u00e9 MA, Karray F, Dousset B, Bertherat J, Legmann P, Bertagna X (2007) Corticotroph tumor progression after adrenalectomy in Cushing\u2019s disease: a reappraisal of Nelson\u2019s syndrome. J Clin Endocrinol Metab 92(1):172\u2013179","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"692_CR22","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1210\/jc.2014-1843","volume":"99","author":"M Fleseriu","year":"2014","unstructured":"Fleseriu M, Findling JW, Koch CA, Schlaffer SM, Buchfelder M, Gross C (2014) Changes in plasma ACTH levels and corticotroph tumor size in patients with Cushing\u2019s disease during long-term treatment with the glucocorticoid receptor antagonist mifepristone. J Clin Endocrinol Metab 99(10):3718\u20133727","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"692_CR23","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1210\/jc.2011-2508","volume":"97","author":"AJ Lely van der","year":"2012","unstructured":"van der Lely AJ, Biller BM, Brue T, Buchfelder M, Ghigo E, Gomez R, Hey-Hadavi J, Lundgren F, Rajicic N, Strasburger CJ, Webb SM, Koltowska-H\u00e4ggstr\u00f6m M (2012) Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab 97(5):1589\u20131597","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"692_CR24","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1210\/jc.2009-1239","volume":"95","author":"JH Buhk","year":"2010","unstructured":"Buhk JH, Jung S, Psychogios MN, Goricke S, Hartz S, Schulz-Heise S, Klingebiel R, Forsting M, Bruckmann H, Dorfler A, Jordan M, Buchfelder M, Knauth M (2010) Tumor volume of growth hormone-secreting pituitary adenomas during treatment with pegvisomant: a prospective multicenter study. J Clin Endocrinol Metab 95(2):552\u2013558","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"692_CR25","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1210\/jc.2013-3318","volume":"99","author":"PJ Caron","year":"2014","unstructured":"Caron PJ, Bevan JS, Petersenn S, Flanagan D, Tabarin A, Pr\u00e9vost G, Maisonobe P, Clermont A (2014) Tumor shrinkage with lanreotide Autogel 120\u00a0mg as primary therapy in acromegaly: results of a prospective multicenter clinical trial. J Clin Endocrinol Metab 99(4):1282\u20131290","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"692_CR26","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/MED.0000000000000065","volume":"21","author":"CM Schooling","year":"2014","unstructured":"Schooling CM (2014) Testosterone and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes 21(3):202\u2013208","journal-title":"Curr Opin Endocrinol Diabetes Obes"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-015-0692-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11102-015-0692-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-015-0692-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T19:06:33Z","timestamp":1553627193000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11102-015-0692-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,5]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["692"],"URL":"https:\/\/doi.org\/10.1007\/s11102-015-0692-z","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,5]]}}}